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AbstrAct
Objective Since 2008, the Oxford Diagnostic Horizon 
Scan Programme has been identifying and summarising 
evidence on new and emerging diagnostic technologies 
relevant to primary care. We used these reports to 
determine the sequence and timing of evidence for new 
point-of-care diagnostic tests and to identify common 
evidence gaps in this process.
Design Systematic overview of diagnostic horizon scan 
reports.
Primary outcome measures We obtained the primary 
studies referenced in each horizon scan report (n=40) and 
extracted details of the study size, clinical setting and design 
characteristics. In particular, we assessed whether each study 
evaluated test accuracy, test impact or cost-effectiveness. 
The evidence for each point-of-care test was mapped against 
the Horvath framework for diagnostic test evaluation.
results We extracted data from 500 primary studies. Most 
diagnostic technologies underwent clinical performance (ie, 
ability to detect a clinical condition) assessment (71.2%), with 
very few progressing to comparative clinical effectiveness 
(10.0%) and a cost-effectiveness evaluation (8.6%), even 
in the more established and frequently reported clinical 
domains, such as cardiovascular disease. The median 
time to complete an evaluation cycle was 9 years (IQR 
5.5–12.5 years). The sequence of evidence generation was 
typically haphazard and some diagnostic tests appear to be 
implemented in routine care without completing essential 
evaluation stages such as clinical effectiveness.
conclusions Evidence generation for new point-of-care 
diagnostic tests is slow and tends to focus on accuracy, 
and overlooks other test attributes such as impact, 
implementation and cost-effectiveness. Evaluation of 
this dynamic cycle and feeding back data from clinical 
effectiveness to refine analytical and clinical performance 
are key to improve the efficiency of point-of-care diagnostic 
test development and impact on clinically relevant outcomes. 
While the ‘road map’ for the steps needed to generate 
evidence are reasonably well delineated, we provide evidence 
on the complexity, length and variability of the actual process 
that many diagnostic technologies undergo.
IntrODuctIOn
Primary care is becoming increasingly 
complex due to a rise in patients with multi-
morbidity and polypharmacy, the pressure of 
short consultation times and the fragmented 
nature of primary and secondary care. 
Delayed or missed diagnoses are the most 
common reason for malpractice claims.1 
Therefore, there is a huge demand for inno-
vations that enable efficient and accurate 
diagnostic assessment within a general practi-
tioner (GP)’s consultation. Consequently, the 
development of point-of-care diagnostic tests 
is currently a hotbed of activity.2 These tests 
have the potential to significantly improve the 
efficiency of diagnostic pathways, providing 
test results within the time frame of a single 
consultation, enabling them to influence 
immediate patient management decisions.
A potential barrier to this innovative activity 
however is the slow and haphazard nature 
of the current pathway to adoption for new 
healthcare technologies.3 This is particularly 
the case for diagnostic tests, where uptake is 
highly variable between settings and notable 
inconsistencies lie in the speed at which they 
are adopted.4 One possible cause of this inef-
ficiency is the slow generation of evidence of 
efficacy relevant to the target clinical settings.
To provide an efficient means of identi-
fying, summarising and disseminating the 
evidence for emerging diagnostic tech-
nologies relevant to primary care settings, 
the Oxford Diagnostic Horizon Scan-
ning Programme was established in 2008 
(currently funded by the National Institute 
Common evidence gaps in point-of-care 
diagnostic test evaluation: a review of 
horizon scan reports
Jan Y Verbakel,1 Philip J Turner,1 Matthew J Thompson,2 Annette Plüddemann,1 
Christopher P Price,1 Bethany Shinkins,3 Ann Van den Bruel1,4
To cite: Verbakel JY, 
Turner PJ, Thompson MJ, 
et al.  Common evidence gaps 
in point-of-care diagnostic 
test evaluation: a review of 
horizon scan reports. BMJ Open 
2017;7:e015760. doi:10.1136/
bmjopen-2016-015760
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files please visit the 
journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2016- 
015760).
Received 29 December 2016
Revised 26 April 2017
Accepted 2 June 2017
1Nuffield Department of Primary 
Care Health Sciences, University 
of Oxford, Oxford, UK
2Primary Care Innovation Lab, 
Department of Family Medicine, 
University of Washington, 
Seattle, Washington, USA
3Test Evaluation Group, AUHE, 
Leeds Institute of Health 
Sciences, University of Leeds, 
Leeds, UK
4Julius Center for Health 
Sciences and Primary Care, 
University of Utrecht, Utrecht, 
The Netherlands
correspondence to
Dr Jan Y Verbakel;  
 jan. verbakel@ phc. ox. ac. uk
Research
strengths and limitations of this study
 ► This study provides the first data on evidence gaps 
in point-of-care diagnostic test evaluation in primary 
care, answering an important clinical need.
 ► We extracted data from multiple consistently 
conducted horizon scan reports.
 ► Our approach might ignore relevant research, 
but systematic evidence gaps identified suggest 
findings to be robust.
 ► Our analyses are limited by the horizon scan report 
publication date.
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Figure 1 Horvath et al11’s cyclical framework for the 
evaluation of diagnostic tests. This framework illustrates the 
key components of the test evaluation process. (1) Analytical 
performance is the aptitude of a diagnostic test to conform 
to predefined quality specifications. (2) Clinical performance 
examines the ability of the biomarker to conform to 
predefined clinical specifications in detecting patients with 
a certain clinical condition or in a physiological state. (3) 
Clinical effectiveness focuses on the test’s ability to improve 
health outcomes that are relevant to an individual patient, 
also allowing comparison (4) of effectiveness between tests. 
(5) A cost-effectiveness analysis compares the changes 
in costs and health effects of introducing a test to assess 
the extent to which the test can be regarded as providing 
value for money. (6) Broader impact encompasses the 
consequences (eg, acceptability, social, psychological, legal, 
ethical, societal and organisational consequences) of testing 
beyond the above-mentioned components.
for Health Research (NIHR) Oxford Diagnostic Evidence 
Co-operative).5 New technologies are identified through 
systematic literature searches and interactions with clini-
cians and the diagnostics industry. These are then priori-
tised using a defined list of criteria.6 Evidence is gathered 
using systematic searches of the published literature and 
supplementary information obtained from manufacturer 
or trade websites and through web search engines, which 
are then used to summarise the analytical and diagnostic 
accuracy of the point-of-care test,7 impact of the test on 
patient outcomes and health processes, cost-effective-
ness of the test and current guidelines for use within 
routine care in the UK. The reports, indexed in the TRIP 
database8 and freely available from the Horizon Scan 
Programme’s website (www. oxford. dec. nihr. ac. uk), are 
actively disseminated to the NIHR Health Technology 
Assessment Programme, the National Institute for Health 
and Clinical Excellence, clinical researchers and commis-
sioners of healthcare services and highlight any further 
research requirements to facilitate evidence-based adop-
tion decisions.
To date, 40 horizon scan reports have been completed, 
all following an identical protocol.
These horizon scan reports provide a unique opportu-
nity to describe the evidence trajectory of new point-of-
care diagnostic tests relevant to primary care settings and 
identify common evidence gaps.
MethODs
This is a descriptive study of all 40 horizon scan 
reports published to date by the Oxford Horizon Scan 
programme. For each horizon scan report, we extracted 
the year of publication and the disease area (classified 
per clinical domain of the International Classification 
of Primary Care—Revised Second Edition (ICPC2-R) 
17) (see online supplementary file 1). We subsequently 
reviewed all studies that were included in the horizon 
scan reports (including systematic reviews) and extracted 
data on year of publication, size of the study, point-of-care 
test device(s) and its intended role. The intended roles 
were defined as ‘triage’, in which the new test is used at 
the start of the clinical pathway, ‘replacement’, in which 
the new test replaces an existing test, either as a faster 
equivalent test or to replace a non-point-of-care labora-
tory test, or ‘add-on’ in which the new test is performed 
at the end of a clinical pathway.9 Depending on the role, 
different types of evidence are required before a new 
point-of-care test can be adopted in routine care.10
We extracted data on study design and primary outcomes 
and used the dynamic evidence framework developed by 
Horvath et al,11 as shown in figure 1, to classify the type of 
evidence, defined as (1) analytical performance, (2) clin-
ical performance, (3) clinical effectiveness, (4) compar-
ative clinical effectiveness, (5) cost-effectiveness and (6) 
broader impact.
Analytical performance is the aptitude of a diag-
nostic test to conform to predefined quality specifica-
tions.12 13 Clinical performance examines the ability of 
the biomarker to conform to predefined clinical specifica-
tions in detecting patients with a particular clinical condi-
tion or in a physiological state.14 Clinical effectiveness 
focuses on the test’s ability to improve health outcomes 
that are relevant to the individual patient.14 A cost-effec-
tiveness analysis compares the changes in costs and in 
health effects of introducing a test to assess the extent 
to which the test can be regarded as providing value for 
money. Broader impact encompasses the consequences 
(eg, acceptability, social, psychological, legal, ethical, soci-
etal and organisational consequences) of testing beyond 
the above-mentioned components.
For point-of-care tests that had evidence on each of 
these components, we calculated the median time (in 
years) for a technology to complete the evaluation cycle.
group.bmj.com on September 7, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Verbakel JY, et al. BMJ Open 2017;7:e015760. doi:10.1136/bmjopen-2016-015760
Open Access
We assessed whether the study was conducted in a setting 
that was relevant for primary care, which was defined as GP 
surgeries (clinics), outpatient clinics, walk-in (or urgent 
care) centres and emergency departments. Data extraction 
was piloted on 20 reports by BS and checked by JV and 
PT after which improvements were made to the final data 
extraction sheet. Three authors (JYV, BS and PJT) inde-
pendently single-extracted data of the included studies.
results
We screened 40 horizon scan reports and extracted data 
from the 500 papers (including 41 systematic reviews) 
referenced by these reports (table 1). Ten horizon scan 
reports examined a point-of-care test relevant to cardio-
vascular disease, six to respiratory diseases and five to 
each of endocrine/metabolic diseases, digestive diseases 
and general/unspecified diseases. A further nine horizon 
scan reports examined a health problem relevant to a 
range of other disease areas. The intended role of the 
test was triage in 14 (35%), replacement in 20 (50%) and 
add-on in 6 (15%) of the 40 horizon scan reports.
We found a median of nine primary studies (IQR 7–15.8) 
per horizon scan report with a median time between first 
and last publication of 10 years (IQR 6.8–13.3). Across 
all horizon scan reports, on average, only 19% (95% CI 
11.4% to 20.7%) of studies were performed in primary 
care (figure 2).
Of all studies, 30.4% (n=152) assessed analytical perfor-
mance of the diagnostic technology, providing evidence 
for this component in 25 (62.5%) of the 40 horizon scan 
reports.
Clinical performance was evaluated in 71.2% (n=356) 
of all studies, while only 18.2% (n=91) of studies evalu-
ated clinical effectiveness of the diagnostic technology. A 
further 10.0% (n=50) compared clinical effectiveness of 
two or more point-of-care tests, and only 8.6% (n=43) of 
the 500 papers evaluated cost-effectiveness (figure 3).
Clinical performance was often assessed earlier (in 16 
tests) or together (in 12) with analytical performance and 
not assessed at all for 6 tests. Broader impact such as accept-
ability was tested before evidence on clinical effectiveness or 
cost-effectiveness was available in 11 horizon scan reports.
Figure 4 shows the number of years between the 
horizon scan report and original paper publication date 
for each evaluation component, split by intended role of 
the point-of-care test. The size of the bubbles represents 
the number of studies proportionate to all studies for the 
intended role, clearly depicting the emphasis on clinical 
performance and paucity of clinical effectiveness studies. 
Furthermore, tests acting as a triage instrument tend 
to spend more time on evidence generation than tests 
replacing an existing one or add-on tests performed at 
the end of the clinical pathway.
Only seven (17.5% (95% CI 7.3% to 32.8%)) horizon 
scan reports included evidence for all evaluation compo-
nents with a median time to complete the evaluation cycle 
of 9 years (IQR 6–13 years). Of these, tests acting as a triage 
instrument (in three reports) had a median of 15 years 
(IQR 10–19) while tests replacing an existing one (in four 
reports) had 9 years (IQR 5–11) (figure 4).
Even in the latter category of diagnostic technology 
replacing existing tests, where nearly half of studies 
(49.4%; n=247) have been performed, there was a clear 
imbalance between studies merely focusing on analyt-
ical or clinical performance (87.4%) and the few studies 
advancing to clinical effectiveness (21.1%).
The sequence of evidence generation over time for the 
seven horizon scan reports which had completed the eval-
uation cycle varied widely, as shown in figure 5. The size of 
the bubbles represents the proportion of studies for each 
evaluation component. The grey arrow shows the sequence 
we would expect, starting at analytical performance (at 12 
o’clock) and completing at broader impact analysis (at 10 
o’clock). The arrows and numbered bubbles represent the 
actual time sequence of evidence generation.
Very few point-of-care test evaluations seem to follow 
the expected sequence. In fact, only the report on point-
of-care C reactive protein testing seemed to generally 
follow a linear temporal sequence from analytical perfor-
mance towards broader impact. Some diagnostic tech-
nology, such as point-of-care international normalised 
ratio (INR) testing, had evidence generated for the 
broader impact component before any other component, 
suggesting that some diagnostic technologies are adopted 
in routine clinical care prior to any published evidence 
on clinical performance or effectiveness.
DIscussIOn
Main findings
Our findings suggest that most point-of-care diagnostic 
tests undergo clinical performance assessment, but 
very few progress to evaluation of their broader impact 
or cost-effectiveness, even in the more established and 
frequently reported clinical domains, such as cardiovas-
cular disease. Some point-of-care tests even skip essential 
stages such as clinical effectiveness, yet are still imple-
mented in routine care. We present a novel way to visu-
alise the gaps in the evidence generation through bubble 
plots and dynamic cycle illustration.
strengths and limitations
Our study provides novel data on common evidence gaps 
in the evaluation of novel point-of-care tests for a wide 
range of clinical conditions. The extensive library of 
existing horizon scan reports and the methodological 
rigour in which they are produced provided an ideal 
opportunity to review the pathway of evidence for novel 
point-of-care diagnostic technologies relevant to the 
primary care settings. The chosen topics of the reports 
result from a comprehensive approach to identify 
new or emerging diagnostic tests, including literature 
searches and interaction with the diagnostics industry 
and clinicians, prioritising technologies relevant to 
primary care. We have, however, no measure of how 
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Figure 2 Setting (%) of the studies by disease area (according to the International Classification of Primary Care-Second 
edition coding).
Figure 3 Test evaluation component by disease area in absolute number (n) of studies.
group.bmj.com on September 7, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 7Verbakel JY, et al. BMJ Open 2017;7:e015760. doi:10.1136/bmjopen-2016-015760
Open Access
Figure 4 Number of years between horizon scan report and original paper publication date by the intended role for each 
evaluation component. Size of bubbles represents number of studies proportionate to all studies for the intended role. BNP, 
B-natriuretic peptide; CRP, C reactive protein; FOBT, faecal occult blood test; HbA1c, glycated haemoglobin; hCG, human 
chorionic gonadotropin; hFABP, heart-type fatty acid-binding protein; INR, international normalised ratio; TSH, thyroid-
stimulating hormone; WBC, white cell count.
reproducible this prioritisation process is, and poten-
tially risks greater or lesser inclusion of various disease 
areas. Evidence from reports on other clinical topics 
might provide different findings. Further to this, our 
review is limited to publication date of each report, thus 
potentially overlooking evidence generated following 
publication. Our approach might arguably ignore rele-
vant (unpublished) research carried out (eg, studies 
performed during test development by industry), but 
the commonalities in the evidence gaps across the 
reports suggest that our findings are robust.
Three authors (JYV, BS and PJT) independently 
single-extracted data of the 500 included studies, making 
it impossible to test for inter-rater agreement.
comparison with the existing literature
Previous evidence has shown that the adoption of a 
diagnostic technology is often insufficient to achieve a 
benefit, and in most cases, a change of care process is 
essential.15 The market for point-of-care tests is growing 
rapidly,16 and there is a clear demand from primary 
care clinicians for these tests to help them diagnose a 
range of conditions.17 18 Critical appraisal of new diag-
nostic technologies is considered essential to facilitate 
implementation.11 Several evaluation frameworks have 
been identified,19 most of which describe the evaluation 
process as a linear process, similar to the staged evalua-
tion of drugs.
Considering the interactions between different evalua-
tion components and the need for certain tests to re-enter 
the evaluation process after updates to the underlying 
technology,20 it may be more realistic to assess these 
components in a cyclic and repetitive process.11
Implications
The slow adoption of novel point-of-care tests may result 
from the paucity of technologies following the expected 
sequence of evidence generation. Specifically, there is a 
need to shift emphasis from examining clinical perfor-
mance of point-of-care tests to comparative clinical 
effectiveness and broader impact assessment. We recom-
mend using a structured dynamic approach, presenting 
the results in a visually appealing manner for both 
industry (during development and pursuit for regulatory 
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Figure 5 Sequence of evidence generation for all seven horizon scan reports completing the full evaluation cycle.  INR, 
international normalised ratio.
approval) and research purposes. Policy-makers and 
guideline developers should be aware of this cyclical 
nature; assuming test evaluation is a linear process results 
in a less efficient evidence generation pathway. For 
example, assessing the cost-effectiveness early on in the 
development phase of novel point-of-care test can help 
determine where exactly it fits in the clinical pathway and 
thus ensure that the evidence subsequently generated is 
relevant to that population and setting.
cOnclusIOns
Considering that evidence generation for new tests takes 
on an average 9 years, test developers need to be aware of 
the time and investment required. While the ‘road map’ 
for the steps needed to generate evidence are reasonably 
well delineated, we provide evidence on the complexity, 
length and variability of the actual process that many 
diagnostic technologies undergo.
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